Earlier this year, this community raised $7.8 million on Wefunder—the most funded campaign in the platform's history—proving how powerful mission‑driven capital can be when aligned with patient impact. Demand exceeded our allocation, so before our next institutional raise, we're reopening a final window for our community to join the next phase of growth.​

The Problem: Injections at Home Are Broken

Patients are stuck with outdated devices where visible needles trigger fear, leading to delayed treatment, errors, and poor adherence—driving them back to clinics and increasing costs. We're changing that. Instead of forcing life to adapt to treatment, our hidden-needle design makes care simple, consistent, and fear-free.​

Our Solution: OnePush™

OnePush is our patented, disc‑shaped push-button auto‑injector designed for real life—drug‑agnostic, partner‑ready, and engineered to turn chronic therapies into a preferred patient experience at scale.​

1. Hidden‑Needle Comfort: Fully automatic—the needle is designed to stay invisible before, during, and after injection, with smooth insertion engineered to reduce sensation and prevent anxiety.​
2. Battlefield‑Grade Engineering: ISO‑aligned, rugged performance aiming for first‑try success in any environment.​
3. Made in America: Scaling automated U.S. manufacturing for speed, quality, and confidence.​

The Opportunity

Sterile injectable delivery is a trillion-dollar global market by 2029. We're positioning OnePush to capture a meaningful share of the $150‑billion GLP‑1 class—including Wegovy®, Ozempic®, and Zepbound®—by pairing blockbuster therapies with device‑driven adherence and potential retail access for millions.​

Since Our Last Wefunder Raise, We've Executed

Validated U.S. manufacturing, increased our global patent count to 23 granted, completed a successful FDA Type C meeting supporting over‑the‑counter potential, and built a pipeline with $800M+ in near‑term licensing opportunities.​

Join Us

We invite you to be part of this next chapter: scaling automated manufacturing, advancing FDA submissions, and commercializing OnePush to put best‑in‑class self‑injection in the hands of millions.

Here's to transforming healthcare, together.

Conor

Founder & CEO, Pirouette

Most patients are still self‑injecting with decades‑old pens and prefilled syringes that force them to stare at exposed needles, manage multiple preparation steps, and hope they did everything correctly. These experiences fuel anxiety, fear, and second‑guessing, and too often lead to delayed doses, avoidable errors, and people quietly abandoning treatment at home.

Needle fear affects over 50% of patients, causing hesitation and poor adherence.

Most devices rely on bulky, plastic-wrapped syringes or outdated auto-injectors that expose the needle, require high force, and weren’t designed with patients in mind.

Even when home use is possible, most injectable medications are still delivered in clinics or pharmacies. Even a routine post-chemotherapy injection can mean driving back to the hospital and home again all for a single shot.

Our patented OnePush™ auto-injector platform simplifies the delivery of all injectable drugs.

With the global injectable medicine market rapidly expanding to nearly $1T, Pirouette’s OnePush auto-injector is designed to improve brand differentiation and adoption by delivering a more patient‑preferred injection experience. Pirouette’s hidden‑needle comfort for home use reduces needle visibility and sensation, helping patients start and stay on essential medications. This leads to both preference and brand loyalty while supporting better long‑term outcomes and quality of life.

With a fully automatic, hidden needle engineered to reduce needle sensation and ease self‑injection anxiety, it strengthens comfort and consistency across a wide range of therapies – from weekly GLP-1s for diabetes and obesity to oncology therapies and HIV medications, as well as hormone injections for IVF.

Pirouette is advancing on every front with global patent protection, U.S. manufacturing already online, fully automated high‑through put capacity in development for build‑out in 2026, and a defined regulatory path that keeps us on track for a first FDA approval in under two years and a second within three. We’re primed to scale and commercialize across priority programs.

We own the IP and have Freedom to Operate Clearance

Pirouette’s competitive advantage is backed by one of the strongest intellectual property positions in the industry. We engaged one of the world’s top intellectual property law firms to conduct a rigorous global patent landscape search. Their conclusion: no other company’s patents stand in our way.

This gives us an unprecedented legal “green light” to manufacture and sell our flagship OnePush™ auto-injector worldwide, without fear of infringing on others or being blocked by competitor lawsuits. This level of clarity is incredibly rare in medtech, and it’s a major moat for Pirouette.

We also fully own the manufacturing IP: every step of the device assembly process, inspection protocol, and production tooling is protected and proprietary. This means we can build, scale, and ship on our own terms—without relying on third parties or risking production disruption. No one else can manufacture OnePush without us.

First, we partner with big pharmaceutical companies. They bring us their blockbuster medicines—drugs that are already proven and approved—and we package them into OnePush. These partnerships generate upfront payments, development milestones, and ongoing royalties every time a dose is sold, creating a steady revenue stream without Pirouette having to sell the drugs ourselves.

Second, we bring our own medicines to market. We take proven, well-established injectable drugs that are losing or have lost patent protection—including blockbuster GLP-1 therapies like semaglutide (the active ingredient in Wegovy® and Ozempic®) and dulaglutide (Trulicity®)—and pair them with OnePush using streamlined FDA pathways called 505(b)(2) and 351(k).

These pathways let us rely on existing safety and effectiveness data for the drug itself, so we only need to run studies proving our device delivers the dose correctly and that patients can use it easily at home. When we launch these products under our own brand, Pirouette captures the full revenue and profit margin—not just royalties.​

Together, these two models give us multiple shots on goal: steady partnership income and the potential for high-margin product sales as we scale.

Disclaimer: Certain information set forth on this page contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws. These are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance. All investments involve risk, including the potential loss of capital. Pirouette’s products presented are not approved by regulatory authorities in any markets and the statements in this presentation represent design intent and are not product claims.